D Hequet1,2, G Harrissart3, D Krief3, L Maumy3, F Lerebours4, E Menet5, C Callens6, R Rouzier3,7. 1. Department of Surgical Oncology, Institut Curie, St Cloud, France. Delphine.hequet@curie.fr. 2. INSERM U900, Institut Curie, St Cloud, France. Delphine.hequet@curie.fr. 3. Department of Surgical Oncology, Institut Curie, St Cloud, France. 4. Department of Medical Oncology, Institut Curie, St Cloud, France. 5. Department of Pathology, Institut Curie, St Cloud, France. 6. Pharmacogenomics Unit, Department of Genetics, Institut Curie, Paris, France. 7. INSERM U900, Institut Curie, St Cloud, France.
Abstract
PURPOSE: Genomic tests can guide the decision to administer adjuvant chemotherapy in women with hormone receptor (HR)-positive, Human Epidermal growth Factor 2 (HER2)-negative breast cancer (BC) at intermediate risk of recurrence. We assessed the decision-making and economic impact of the Prosigna test in a real-life setting. METHODS: Retrospective cohort study of HR + , HER2- BC patients managed from 2016 to 2020, potential candidates for adjuvant chemotherapy, at intermediate risk of recurrence, in whom a Prosigna test was performed according to contemporary guidelines. The additional cost of chemotherapy over one year in terms of direct medical and non-medical costs was estimated in this study to be €9,737 (derived from a previous study, NCT02813317). The cost of the Prosigna test, as defined by the reimbursement system, was €1,849. RESULTS: Among the 809 patients included in this study, 2.3 Prosigna tests had to be performed to avoid adjuvant chemotherapy for one patient. The number of tests that had to be performed to avoid chemotherapy for one patient was higher for patients with grade 3 tumors and pN1mic axillary node involvement and lower for grade 1 tumors or in the absence of axillary node involvement (pN0), but did not vary according to the 10-year overall survival gain predicted by the Predict online test. The cost saving related to withholding of adjuvant chemotherapy for one patient on the basis of the Prosigna test results was €5,485. CONCLUSION: We present one of the largest cohorts of HR + , HER2- BC patients at intermediate risk of recurrence, in whom a Prosigna test was used to guide the adjuvant therapy decision in a real-life setting, resulting in a 44% decrease in the indication for chemotherapy.
PURPOSE: Genomic tests can guide the decision to administer adjuvant chemotherapy in women with hormone receptor (HR)-positive, Human Epidermal growth Factor 2 (HER2)-negative breast cancer (BC) at intermediate risk of recurrence. We assessed the decision-making and economic impact of the Prosigna test in a real-life setting. METHODS: Retrospective cohort study of HR + , HER2- BC patients managed from 2016 to 2020, potential candidates for adjuvant chemotherapy, at intermediate risk of recurrence, in whom a Prosigna test was performed according to contemporary guidelines. The additional cost of chemotherapy over one year in terms of direct medical and non-medical costs was estimated in this study to be €9,737 (derived from a previous study, NCT02813317). The cost of the Prosigna test, as defined by the reimbursement system, was €1,849. RESULTS: Among the 809 patients included in this study, 2.3 Prosigna tests had to be performed to avoid adjuvant chemotherapy for one patient. The number of tests that had to be performed to avoid chemotherapy for one patient was higher for patients with grade 3 tumors and pN1mic axillary node involvement and lower for grade 1 tumors or in the absence of axillary node involvement (pN0), but did not vary according to the 10-year overall survival gain predicted by the Predict online test. The cost saving related to withholding of adjuvant chemotherapy for one patient on the basis of the Prosigna test results was €5,485. CONCLUSION: We present one of the largest cohorts of HR + , HER2- BC patients at intermediate risk of recurrence, in whom a Prosigna test was used to guide the adjuvant therapy decision in a real-life setting, resulting in a 44% decrease in the indication for chemotherapy.
Entities:
Keywords:
Breast cancer; Cost saving; Decision impact; Genomic test
Authors: William J Gradishar; Benjamin O Anderson; Jame Abraham; Rebecca Aft; Doreen Agnese; Kimberly H Allison; Sarah L Blair; Harold J Burstein; Chau Dang; Anthony D Elias; Sharon H Giordano; Matthew P Goetz; Lori J Goldstein; Steven J Isakoff; Jairam Krishnamurthy; Janice Lyons; P Kelly Marcom; Jennifer Matro; Ingrid A Mayer; Meena S Moran; Joanne Mortimer; Ruth M O'Regan; Sameer A Patel; Lori J Pierce; Hope S Rugo; Amy Sitapati; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; Erica M Stringer-Reasor; Melinda L Telli; John H Ward; Jessica S Young; Jennifer L Burns; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2020-04 Impact factor: 11.908
Authors: Harold J Burstein; Christina Lacchetti; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen A Gelmon; Sharon H Giordano; Clifford A Hudis; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs Journal: J Clin Oncol Date: 2018-11-19 Impact factor: 44.544
Authors: Berit Maria Müller; Elke Keil; Annika Lehmann; Klaus-Jürgen Winzer; Christiane Richter-Ehrenstein; Judith Prinzler; Nikola Bangemann; Angela Reles; Sylvia Stadie; Winfried Schoenegg; Jan Eucker; Marcus Schmidt; Frank Lippek; Korinna Jöhrens; Stefan Pahl; Bruno Valentin Sinn; Jan Budczies; Manfred Dietel; Carsten Denkert Journal: PLoS One Date: 2013-06-27 Impact factor: 3.240